Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.18 – $0.37
3% from low
Exchange
OTC Link
CS
Borrow rate
5.58%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $412.0K | $2.4M | $1.3M | $1.0M | $1.7M | $1.9M | $1.4M | $1.4M |
| Cost of revenue | $18.2M | $14.1M | $33.6M | $20.3M | $1.5M | $27.7M | $2.0M | $2.3M |
| Gross profit | −$17.7M | −$11.7M | −$32.3M | −$19.3M | $135.0K | −$25.8M | $1.4M | −$959.0K |
| Gross margin | -4306.3% | -485.3% | -2505.5% | -1920.7% | 8.0% | -1335.3% | 100.0% | -69.6% |
| R&D | $18.2M | $14.1M | $33.6M | $20.3M | $35.5M | $27.7M | $34.9M | $28.8M |
| Operating income | −$41.5M | −$27.5M | −$86.6M | −$52.7M | −$67.2M | −$55.5M | −$66.5M | −$59.9M |
| EBITDA | −$24.6M | −$17.8M | −$520.9M | $184.7M | −$97.4M | −$55.3M | −$73.6M | −$57.6M |
| Net income | −$35.8M | −$20.8M | −$529.8M | $179.1M | −$105.0M | −$62.6M | −$83.8M | −$61.5M |
| Net margin | -8687.9% | -863.6% | -41039.6% | 17823.5% | -6240.8% | -3240.1% | -6062.1% | -4461.3% |
| EPS (diluted) | -0.12 | -0.04 | -0.73 | -0.06 | -0.10 | -0.06 | -0.07 | -0.04 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2M | $-0.05 | $-0.05–$-0.05 | 1 |
| 2027 | $39M | $-0.07 | $-0.07–$-0.07 | 1 |
Forward consensus · source: Financial Modeling Prep
NORTHWEST BIOTHRPUTCS INC
No one on the platform currently holds NWBO.
No tracked institution reports a position in NWBO as of their last filing.
| Execution date | Ratio |
|---|---|
| 2012-09-26 | 1-for-16reverse |
No one on the platform has traded NWBO yet.
| $342M |
| — |
| FGHQFFrontage Holdings Corporation | $0.14 | +0.00% | $274M | — |
| HLOSFHealios K.K. | $1.80 | +0.00% | $194M | — |
Source: Financial Modeling Prep · peers by sector/industry
$NWBO I got copied again! Must have been good! 🤣 https://x.com/i/status/2071866868164653566
View on StockTwits ↗$NWBO @None_ "The argument undermines itself. You begin by correctly saying: "It's a patent, not a clinical trial." That's true. But then you immediately leap to: "That's the kind of shift that rewrites oncology!" Those two statements are incompatible." ? Seriously, are you actually trying to use AI for your dumb argument chains? Man, you clearly have no idea how AI actually works! If you want to talk, don’t rip a single sentence out of context that has nothing to do with the original argument. “Patent → supercharging → rewriting oncology.” That’s the sequence! A blind man trying to tell the world the Earth is flat. What a joke of a figure!
View on StockTwits ↗$NWBO just adding what I can as I wait. 1125 order place for .183!
View on StockTwits ↗$NWBO Irony would be our company going to the UK to seek independence from the OTC.
View on StockTwits ↗$NWBO Its tuesday and approval will come Soon this shitshow is over. Lfg🦬💎🦍
View on StockTwits ↗$NWBO I am a bit tired of waiting for anything to happen therefore I decided it’s time to go fishing ! Lofoten Islands Norway Baby ! See ya! 👋 Îll be back in September…
View on StockTwits ↗$NWBO using this logic there is a monthly approval. Always happens close or approval. We are nowhere near approval! Absolutely nonsense statement One of the biggest clowns on X
View on StockTwits ↗$NWBO if Mgmt gives some Donations thru Lobbiest Lord or middle man in U.K .... .. things can be dramatically change .....
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Trading at 152.5× sales vs its 383.3× historical median P/S.
Fair value ≈ $0.46 · price $0.18 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.